ライフサイエンスコーパス: fluticasone

1 HLMCs were present, but this was reversed by fluticasone.

2 any effect on suppression of inflammation by fluticasone.

3 cantly lower doses and with lower costs than fluticasone.

4 95% CI, 0.73-0.93) than patients started on fluticasone.

5 nt prescribed HFA-beclomethasone rather than fluticasone.

6 n with the corticosteroids dexamethasone and fluticasone.

7 e to severe COPD can be reduced by high-dose fluticasone.

8 100 microg twice daily) to receive continued fluticasone (100 microg twice daily) (169 patients), mon

9 h asthma that was well controlled by inhaled fluticasone (100 microg twice daily) to receive continue

10 t (5 or 10 mg each night) (166 patients), or fluticasone (100 microg) plus salmeterol (50 microg) eac

11 y TNFalpha alone was completely abrogated by fluticasone (100 nM), dexamethasone (1 microM), or budes

12 pregnancy (n = 1231; 79.9% budesonide, 17.6% fluticasone, 5.4% beclomethasone, and 0.9% other or unsp

13 rol (50 mug) plus the inhaled glucocorticoid fluticasone (500 mug) twice daily.

14 onsiveness to methacholine, received inhaled fluticasone (880 microg daily) for 12 weeks.

15 t this hypothesis, we studied the effects of fluticasone, AC, or both on AMos of C57BL/6 mice in vitr

16 Patients receiving fluticasone achieved a significantly higher rate of clin

17 e hydrofluoroalkane (HFA)-beclomethasone and fluticasone administered through a pressurized metered-d

18 1), salmeterol (73 mL, 46-101, p<0.0001), or fluticasone alone (95 mL, 67-122, p<0.0001).

19 ve fluticasone propionate plus salmeterol or fluticasone alone for 26 weeks.

20 eceive either fluticasone with salmeterol or fluticasone alone for 26 weeks.

21 ard ratio with fluticasone-salmeterol versus fluticasone alone was 1.28 (95% confidence interval [CI]

22 Noninferiority of fluticasone-salmeterol to fluticasone alone was defined as an upper boundary of th

23 ated event that was similar to the risk with fluticasone alone.

24 a-related events than did those who received fluticasone alone.

25 e fluticasone-salmeterol group and 21 in the fluticasone-alone group had a serious asthma-related eve

26 sone-salmeterol group and 309 (10.0%) in the fluticasone-alone group had a severe asthma exacerbation

27 Fluticasone, an inhaled steroid commonly used to treat a

28 with fluticasone/salmeterol (64% vs 23% 2.5x fluticasone and 13% fluticasone/montelukast in the Best

29 In vitro fluticasone and budesonide reduced MR1 surface expressio

30 reated with topical corticosteroids, such as fluticasone and budesonide, or dietary strategies, such

31 nd CCL5 by TNF-alpha was insensitive to both fluticasone and dexamethasone in ASM cells from severe a

32 ing their first ICS as HFA-beclomethasone or fluticasone and matched on baseline demographic characte

33 interferon (IFN) beta was administered with fluticasone and rhinovirus 1B in both groups of mice.

34 asal recombinant IFN beta (10(4) units) with fluticasone and rhinovirus 1B led to upregulation of int

35 P-10 compared with control mice treated with fluticasone and rhinovirus alone and improved viral clea

36 All participants received high-dose fluticasone and salmeterol and continued other pre-study

37 study evaluates the contribution of inhaled fluticasone and salmeterol, alone or combined, to the re

38 d additively and synergistically enhanced by fluticasone and salmeterol, respectively.

39 ha-treated HASM cells, which was enhanced by fluticasone and salmeterol.

40 nd additively enhanced by the glucocorticoid fluticasone and the beta(2)-agonist salmeterol, whereas

41 ilanterol); a control arm (not given inhaled fluticasone); and pre-randomisation measurements of bloo

42 and 336 patients randomized to montelukast, fluticasone, and placebo, respectively.

43 15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induc

44 from the run-in period of open-label inhaled fluticasone, and the treatment periods for subjects rand

45 Combined activity of salmeterol and fluticasone at equimolar concentrations had no effect on

46 ntrolled with the use of twice-daily inhaled fluticasone can be switched to once-daily fluticasone pl

47 fluticasone DPI - 445; budesonide DPI - 268; fluticasone-CFC MDI - 111.

48 e dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered dose inhaler [MDI], flunisolide-

49 Halcinonide, fluticasone, clobetasol, and fluocinonide provide an unp

50 tified four FDA-approved drugs, halcinonide, fluticasone, clobetasol, and fluocinonide, as Smo agonis

51 a2-agonist/inhaled corticosteroid salmeterol/fluticasone combination 50/500 mug in patients with one

52 nced by suppressed BAL neutrophil numbers in fluticasone compared with control mice (0.021 x 10(5) [0

53 salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of

54 sponse returned to normal 9 months after the fluticasone dose was reduced to 500 micrograms/day.

55 lomethasone doses were lower (P < .001) than fluticasone doses (median, 320 mug/d [interquartile rang

56 inolone-CFC - 787; beclomethasone-CFC - 548; fluticasone DPI - 445; budesonide DPI - 268; fluticasone

57 iamcinolone-CFC), only the placebo group and fluticasone DPI did not demonstrate a significant dose-r

58 [CFC], budesonide dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered dose inhaler [M

59 ects randomized to (1) continued twice daily fluticasone (F), (2) once daily fluticasone plus salmete

60 More importantly, fluticasone failed to induce GRE-dependent gene transcri

61 ium was significantly superior to salmeterol/fluticasone for the prevention of exacerbations (all sev

62 95% CI 0.75-1.14]) with similar findings for fluticasone furoate (0.90 [0.72-1.11]) and vilanterol (0

63 , vilanterol (25 mug), or the combination of fluticasone furoate (100 mug) and vilanterol (25 mug).

64 locks to receive once daily inhaled placebo, fluticasone furoate (100 mug), vilanterol (25 mug), or t

65 ear [95% CI 1-15]) with similar findings for fluticasone furoate (difference 8 mL per year [95% CI 1-

66 the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) and long-acting beta(2) -agonis

67 Fluticasone furoate (FF) is a novel, once-daily ICS asth

68 Genotyping and imputation was performed in fluticasone furoate (FF) or fluticasone propionate-treat

69 ontrolled trial, once-daily inhaled placebo, fluticasone furoate (FF; 100 mug), vilanterol (VI; 25 mu

70 ere pretreated with either cetirizine 10 mg, fluticasone furoate 27.5 mug, or placebo to alleviate th

71 randomly assigned to initiate treatment with fluticasone furoate and vilanterol (n=2114) or usual car

72 V1) and the increased risk of pneumonia with fluticasone furoate and vilanterol compared with vilante

73 ightened cardiovascular risk, treatment with fluticasone furoate and vilanterol did not affect mortal

74 hose on usual care (977 [71%] of 1373 in the fluticasone furoate and vilanterol group vs 784 [56%] of

75 f a once-daily treatment regimen of combined fluticasone furoate and vilanterol improved asthma contr

76 Across all doses of inhaled corticosteroids, fluticasone furoate and vilanterol reduced exacerbations

77 er for patients who initiated treatment with fluticasone furoate and vilanterol than for those on usu

78 fractures were reported more frequently with fluticasone furoate and vilanterol than with vilanterol

79 , a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with a

80 We hypothesised that fluticasone furoate and vilanterol would prevent more ex

81 patients (605 assigned to usual care, 602 to fluticasone furoate and vilanterol) had a baseline ACT s

82 ms (fluticasone propionate and salmeterol or fluticasone furoate and vilanterol); a control arm (not

83 nts from baseline in patients initiated with fluticasone furoate and vilanterol, compared with 2.8 po

84 Reductions in exacerbations with fluticasone furoate and vilanterol, compared with vilant

85 COPD to a once-daily inhaled combination of fluticasone furoate at a dose of 100 mug and vilanterol

86 tion; 4111 in the placebo group, 4135 in the fluticasone furoate group, 4118 in the vilanterol group,

87 18% in the combination group, and 17% in the fluticasone furoate group, and 17% in the vilanterol gro

88 roup, 6% in the combination group, 5% in the fluticasone furoate group, and 4% in the vilanterol grou

89 vilanterol plus 50 mug, 100 mug, or 200 mug fluticasone furoate in patients with moderate-to-severe

90 ng-term effect of the inhaled corticosteroid fluticasone furoate on exacerbation frequency.

91 ined with either 50 mug, 100 mug, or 200 mug fluticasone furoate once daily.

92 Addition of fluticasone furoate to vilanterol was associated with a

93 led combination of either 100 mug or 200 mug fluticasone furoate with 25 mug vilanterol or optimised

94 Fluticasone furoate, alone or in combination with vilant

95 a combined treatment of the corticosteroid, fluticasone furoate, and the long-acting beta agonist, v

96 ative reduction; p=0.137) or the components (fluticasone furoate, HR 0.91 [0.77-1.08]; p=0.284; vilan

97 mug and vilanterol at a dose of 25 mug (the fluticasone furoate-vilanterol group) or to usual care (

98 s serious adverse events of pneumonia in the fluticasone furoate-vilanterol group.

99 (95% confidence interval, 1.1 to 15.2), with fluticasone furoate-vilanterol therapy than with usual c

100 al pro-apoptotic effect of dexamethasone and fluticasone furoate.

101 aring 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 mug/62.5

102 led corticosteroid/long-acting beta2-agonist fluticasone furoate/vilanterol 100/25 mug or placebo (7-

103 bation rate was noted between the 200/25 mug fluticasone furoate/vilanterol group and the vilanterol

104 ight deaths from pneumonia were noted in the fluticasone furoate/vilanterol groups compared with none

105 e and severe exacerbations were noted in all fluticasone furoate/vilanterol groups than in the vilant

106 e and severe exacerbations were noted in all fluticasone furoate/vilanterol groups than in the vilant

107 Fluticasone furoate/vilanterol safety profile was simila

108 P < 0.001) reduction in residual volume with fluticasone furoate/vilanterol versus placebo.

109 -glycopyrronium group than in the salmeterol-fluticasone group (0.98 vs. 1.19; rate ratio, 0.83; 95%

110 -glycopyrronium group than in the salmeterol-fluticasone group (3.59 vs. 4.03; rate ratio, 0.89; 95%

111 e first exacerbation than did the salmeterol-fluticasone group (71 days [95% CI, 60 to 82] vs. 51 day

112 -glycopyrronium group than in the salmeterol-fluticasone group (hazard ratio, 0.78; 95% CI, 0.70 to 0

113 copyrronium group and 4.8% in the salmeterol-fluticasone group (P=0.02).

114 Fewer patients in the fluticasone group withdrew from the study due to lung-re

115 e combination-therapy group and 18.3% in the fluticasone group) than in the placebo group (12.3%, P<0

116 opyrronium group, and 1682 to the salmeterol-fluticasone group.

117 5% in the salmeterol group, and 16.0% in the fluticasone group.

118 Fluticasone group: n=84, median age 14.6 yr, mean (SD) F

119 The efficacy and safety of fluticasone has been established at recommended doses of

120 Patients treated with fluticasone improved significantly more rapidly (median

121 fter therapy with the inhaled corticosteroid fluticasone in independent cohorts.

122 bo-controlled trial of pre-emptive high-dose fluticasone in preschoolers with URTI-induced asthma.

123 bo-controlled trial of pre-emptive high-dose fluticasone in preschoolers with virus-induced asthma.

124 pyrronium was more effective than salmeterol-fluticasone in preventing COPD exacerbations in patients

125 feriority but also superiority to salmeterol-fluticasone in reducing the annual rate of all COPD exac

126 to continued triple therapy or withdrawal of fluticasone in three steps over a 12-week period.

127 By contrast, fluticasone increased MUC5AC proteins (158.2 arbitrary u

128 KCa3.1 channel blockade also restored fluticasone-induced GC receptor-alpha phosphorylation at

129 Fluticasone-induced GRalpha nuclear translocation, phosp

130 om hospital patients were given a salmeterol/fluticasone inhaler with an INCA device attached.

131 Despite increasing viral loads, fluticasone inhibited rhinovirus-induced airway inflamma

132 nificantly lower for HFA-beclomethasone than fluticasone (mean, $1869 [95% CI, $1727-$2032] vs $2259

133 Fluticasone/salmeterol and fluticasone monotherapy decreased peripheral airway smoo

134 Fluticasone/salmeterol and fluticasone monotherapy equally reverse peripheral airwa

135 meterol (64% vs 23% 2.5x fluticasone and 13% fluticasone/montelukast in the Best ADd-on Therapy Givin

136 iver homogenate reference sample, except for fluticasone, nicardipine, and sorafenib which suffer fro

137 indacaterol-glycopyrronium versus salmeterol-fluticasone on the rate of COPD exacerbations was indepe

138 the fluticasone-salmeterol group than in the fluticasone-only group (hazard ratio, 0.79; 95% CI, 0.70

139 pared with 597 of 5845 patients (10%) in the fluticasone-only group (P<0.001).

140 no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthma-related intubati

141 ol group and 38 events in 33 patients in the fluticasone-only group.

142 e asthma exacerbations than did those in the fluticasone-only group.

143 ere defined as daily therapy with 500 mug of fluticasone or greater with or without a long-acting bet

144 received fluticasone; they then took either fluticasone or placebo for 6 mo.

145 0% of patients assigned to receive continued fluticasone or switched to treatment with fluticasone pl

146 45% (montelukast, P < .05 vs placebo), 49% (fluticasone, P < .001 vs placebo), and 39% (placebo); th

147 one twice daily (ICS step-up), 100 microg of fluticasone plus 50 microg of a long-acting beta-agonist

148 Mice treated with fluticasone plus AC before infection with viable pneumoc

149 ment to the lungs at 48 h postinfection, and fluticasone plus AC less markedly reduced in vitro media

150 Fluticasone plus AC significantly reduced in vitro AMo k

151 Fluticasone plus AC significantly reduced TLR4-stimulate

152 twice daily fluticasone (F), (2) once daily fluticasone plus salmeterol (F + S), or (3) once daily o

153 se budesonide plus formoterol, or fixed-dose fluticasone plus salmeterol for 6 months.

154 se budesonide plus formoterol and fixed-dose fluticasone plus salmeterol for 7 months.

155 ed fluticasone or switched to treatment with fluticasone plus salmeterol had treatment failure, as co

156 ed fluticasone can be switched to once-daily fluticasone plus salmeterol without increased rates of t

157 thasone, methylprednisolone, budesonide, and fluticasone, potentiated TGF-beta signaling by the Acvrl

158 Fluticasone produced a wide spectrum of changes in the b

159 C57BL/6 mice were intranasally dosed with fluticasone propionate (1 mg/kg) or vehicle (dimethyl su

160 ma and treated them for 30 days with inhaled fluticasone propionate (1,760 microg/day) followed by a

161 ng patients receiving medications containing fluticasone propionate (19.6% in the combination-therapy

162 twice daily), and the inhaled glucocorticoid fluticasone propionate (500 mug twice daily) during a 6-

163 percentage difference, -15%; P = .0115), and fluticasone propionate (absolute difference, -1.64; perc

164 ve asthma predictive index to treatment with fluticasone propionate (at a dose of 88 mug twice daily)

165 fits of combining an inhaled corticosteroid, fluticasone propionate (F), with an inhaled long-acting

166 FF 50 mcg dosed in the evening, twice-daily fluticasone propionate (FP) 100 mcg or placebo.

167 lind, crossover study evaluating twice daily fluticasone propionate (FP) 100 mug, FP 500 mug and plac

168 crossover study and inhaled single doses of fluticasone propionate (FP) 100 mug, FP 500 mug, salmete

169 ment with salmeterol 50 microg combined with fluticasone propionate (FP) 250 microg, salmeterol 50 mi

170 , mean age 64 yr, were randomized to receive fluticasone propionate (FP) 500 microg twice daily (376

171 e efficacy and safety of high-dose swallowed fluticasone propionate (FP) and dose reduction in patien

172 We evaluated the effects of fluticasone propionate (FP) and of salmeterol (SM), on t

173 ce were studied to determine whether inhaled fluticasone propionate (FP) could attenuate airway infla

174 we determined the effects of salmeterol and fluticasone propionate (FP) in seven steroid-naive patie

175 aimed to determine the efficacy of swallowed fluticasone propionate (FP) in the treatment of eosinoph

176 ); low (L), medium (M) and high (H) doses of fluticasone propionate (FP) L: 330 microg, M: 770 microg

177 ddition, the effects of IL-4, IFN-gamma, and fluticasone propionate (FP) on nasal epithelial cells we

178 antiinflammatory agents montelukast (ML) and fluticasone propionate (FP) on Qaw in 12 patients with m

179 the efficacy of MP-AzeFlu (Dymista((R)) ) vs fluticasone propionate (FP), (both 1 spray/nostril bid),

180 hages, matured in the presence or absence of fluticasone propionate (FP), and their ability to initia

181 ect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition o

182 ent study was to determine if an inhaled GS, fluticasone propionate (FP), similarly leads to vasocons

183 H3N2 and either or not treated with inhaled fluticasone propionate (FP), systemic corticosteroids (P

184 estigated the effects of importin-7 siRNA on fluticasone propionate (FP)-induced GR nuclear localizat

185 age I to II) before and after treatment with fluticasone propionate (FP)/salmeterol (SM) (50/500, 4 w

186 and assessed the effects of a 2-wk course of fluticasone propionate (FP; 440 microg daily) on these p

187 Two puffs (total dose, 200 microgram) of fluticasone propionate (n = 47) or placebo nasal spray (

188 propionate treatment regimens than with oral fluticasone propionate (with the exception of PEF rates

189 (with the exception of PEF rates for inhaled fluticasone propionate 100 micrograms) or placebo treatm

190 allergy were treated with run-in medication (fluticasone propionate 100 mug bid) during 2 weeks befor

191 d, double-blind, controlled study of inhaled fluticasone propionate 100 mug twice daily in young chil

192 re not under control by 3 months, open-label fluticasone propionate 100 mug twice daily was added to

193 wder 100 or 500 micrograms twice daily, oral fluticasone propionate 20 mg once daily, or placebo duri

194 lind study to placebo (n = 73) or salmeterol/fluticasone propionate 50/500 microg (n = 67) twice dail

195 29-02 (a novel formulation of azelastine and fluticasone propionate [FP]) in patients with moderate-t

196 The mortality rate for salmeterol alone or fluticasone propionate alone did not differ significantl

197 inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years.

198 ve with a combination product (100 microg of fluticasone propionate and 50 microg of salmeterol [FSC]

199 gate the effects of common asthma treatments fluticasone propionate and beta(2) agonists salmeterol a

200 n the 12 h after dosing, we monitored plasma fluticasone propionate and cortisol concentrations by ma

201 (inflammation and bronchoconstriction) with fluticasone propionate and salmeterol in a combination p

202 COPD that had: inhaled corticosteroid arms (fluticasone propionate and salmeterol or fluticasone fur

203 est that the therapeutic benefits of inhaled fluticasone propionate are mediated through topical effe

204 whether the therapeutic benefits of inhaled fluticasone propionate are mediated through topical or s

205 When high doses of fluticasone propionate are used, growth may be retarded

206 Systemic exposure to fluticasone propionate as assessed by trough plasma conc

207 aring salmeterol at a dose of 50 microg plus fluticasone propionate at a dose of 500 microg twice dai

208 tiotropium, 100 mug salmeterol, and 1000 mug fluticasone propionate daily for 6 weeks and were then r

209 0.3 +/- 15.2 years; ACT score, 14.6 +/- 3.8; fluticasone propionate dose, 718 +/- 470 mug).

210 The early use of inhaled fluticasone propionate for wheezing in preschool childre

211 Patients receiving inhaled fluticasone propionate had a significantly greater proba

212 The combination of salmeterol and fluticasone propionate has a broad spectrum of antiinfla

213 We investigated the pharmacokinetics of fluticasone propionate in patients with asthma receiving

214 Some studies of high-dose fluticasone propionate in patients with no or mild asthm

215 Systemic availability of fluticasone propionate is substantially less in patients

216 BI 671800 (50, 200, and 400 mg twice daily), fluticasone propionate nasal spray (200 mug once daily),

217 this study was to assess effects of inhaled fluticasone propionate on rhinovirus infection in vivo,

218 core >/=1.5) after uptitration to 1000 mug/d fluticasone propionate or greater were randomized to 3 o

219 r time compared with patients receiving oral fluticasone propionate or placebo (p = 0.001).

220 wer in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95

221 ukast (our primary hypothesis) or once-daily fluticasone propionate plus salmeterol (our secondary hy

222 xacerbations in the previous year to receive fluticasone propionate plus salmeterol or fluticasone al

223 nd, run-in period were randomized to inhaled fluticasone propionate powder 100 or 500 micrograms twic

224 The potent topical glucocorticoid fluticasone propionate significantly suppressed dsRNA-de

225 ve analyses (AUC12) was higher with the oral fluticasone propionate than with the two inhaled flutica

226 tic children after introduction of high-dose fluticasone propionate treatment (dry powder).

227 icasone propionate than with the two inhaled fluticasone propionate treatment groups.

228 point were significantly higher with inhaled fluticasone propionate treatment regimens than with oral

229 tes, both 10 mg/d montelukast and 250 mug of fluticasone propionate twice daily significantly increas

230 evaluates 10 mg/d montelukast and 250 mug of fluticasone propionate twice daily, each compared with p

231 Fluticasone propionate was introduced in 1993 in the UK

232 rdation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppre

233 over the benchmark inhaled corticosteroid 3 (fluticasone propionate) and prolonged the inhibition of

234 ly (fluticasone propionate), INCS on demand (fluticasone propionate) or oral antihistamine on demand

235 nolone acetonide, clobetasol propionate, and fluticasone propionate) predominantly accounted for GR a

236 ta2-agonist (salmeterol) and corticosteroid (fluticasone propionate) will reduce inflammation.

237 Patients received either INCS daily (fluticasone propionate), INCS on demand (fluticasone pro

238 oth TH1 and TH2 cytokines, was additive with fluticasone propionate, and inhibited cytokine release f

239 the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination in c

240 the results after adjustment for open-label fluticasone propionate, nor between the two groups in th

241 and primary cultures], roflumilast enhanced fluticasone propionate-induced GRE-dependent transcripti

242 was performed in fluticasone furoate (FF) or fluticasone propionate-treated patients with asthma from

243 combination with an inhaled glucocorticoid, fluticasone propionate.

244 daily for 7 days inhaled (via spacer device) fluticasone propionate.

245 group than in controls 4-12 h after inhaled fluticasone propionate.

246 Inhaler monitors recorded fluticasone propionate/salmeterol adherence (covertly fo

247 We found that the GC fluticasone rapidly and dose-dependently increased AC up

248 Fluticasone rapidly suppressed AMo expression of SIRPalp

249 superior or similar benefits over salmeterol/fluticasone regardless of blood eosinophil levels in pat

250 atics and PP5 knockdown using siRNA restored fluticasone repressive action on chemokine production an

251 l blockade led to a significant reduction of fluticasone-resistant CX3CL1, CCL5, and CCL11 gene and p

252 relapse in 14 randomized controlled trials (fluticasone: risk ratio, 1.31; 95% CI, 1.02-1.68; tacrol

253 LAME (Effect of Indacaterol Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, whi

254 ic horses (6 horses/group) were treated with fluticasone, salmeterol, fluticasone/salmeterol, or with

255 to 2.27), which showed the noninferiority of fluticasone-salmeterol (P=0.006).

256 Among the 6208 patients, 27 patients in the fluticasone-salmeterol group and 21 in the fluticasone-a

257 A total of 265 patients (8.5%) in the fluticasone-salmeterol group and 309 (10.0%) in the flut

258 events, with 36 events in 34 patients in the fluticasone-salmeterol group and 38 events in 33 patient

259 ere asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-onl

260 io for a serious asthma-related event in the fluticasone-salmeterol group was 1.03 (95% confidence in

261 ccurring in 480 of 5834 patients (8%) in the fluticasone-salmeterol group, as compared with 597 of 58

262 Patients receiving fluticasone-salmeterol had fewer severe asthma exacerbat

263 Noninferiority of fluticasone-salmeterol to fluticasone alone was defined

264 ere hospitalizations); the hazard ratio with fluticasone-salmeterol versus fluticasone alone was 1.28

265 lung function cluster had best response with fluticasone/salmeterol (64% vs 23% 2.5x fluticasone and

266 e advertised during the period examined: (1) fluticasone/salmeterol (Advair), (2) mometasone furoate

267 ve effects in patients with asthma receiving fluticasone/salmeterol (FP/SM) combination and FP alone.

268 She is on fluticasone/salmeterol 500/50 mug one inhalation twice d

269 Fluticasone/salmeterol and fluticasone monotherapy decre

270 Fluticasone/salmeterol and fluticasone monotherapy equal

271 In conclusion, this study shows that fluticasone/salmeterol combination decreases extracellul

272 Only fluticasone/salmeterol decreased bronchoalveolar neutrop

273 In central airways, fluticasone/salmeterol reversed extracellular matrix rem

274 ) were treated with fluticasone, salmeterol, fluticasone/salmeterol, or with antigen avoidance for 12

275 l subgroups, and at no cutoff was salmeterol/fluticasone superior to indacaterol/glycopyrronium.

276 was higher in patients receiving salmeterol/fluticasone than indacaterol/glycopyrronium in both the

277 NCS on-demand group used on average 61% less fluticasone than patients in the INCS daily group during

278 In children receiving fluticasone, the ADYC score was significantly lower vers

279 he 2-mo run-in period, all patients received fluticasone; they then took either fluticasone or placeb

280 The addition of fluticasone to xylometazoline and antimicrobial therapy

281 type I and III IFNs in the airways (for the fluticasone-treated group compared with controls: mean I

282 d IL-1beta-induced IL-6 production; however, fluticasone treatment caused a reduction of IL-6 protein

283 urfactant protein D inhibited AC uptake, and fluticasone treatment rapidly reversed this inhibition.

284 At 24 h post infection, fluticasone treatment suppressed rhinovirus induction of

285 Our findings suggest that fluticasone treatment suppresses rhinovirus-induced airw

286 airway hyperresponsiveness after 6 weeks of fluticasone treatment.

287 specific microbiota members were seen after fluticasone treatment.

288 in random order for 16 weeks: 250 microg of fluticasone twice daily (ICS step-up), 100 microg of flu

289 (n=374), 50 microg salmeterol and 500 microg fluticasone twice daily (n=358), or placebo (n=361) for

290 g salmeterol twice daily (n=372), 500 microg fluticasone twice daily (n=374), 50 microg salmeterol an

291 twice daily (LABA step-up), or 100 microg of fluticasone twice daily plus 5 or 10 mg of a leukotriene

292 trolled asthma while receiving 100 microg of fluticasone twice daily, to receive each of three blinde

293 95% confidence interval) of 0.59 (0.23-1.48) fluticasone versus placebo.

294 fidence interval) of 1.07 (0.68 to 1.70) for fluticasone versus placebo.

295 significantly lower in children treated with fluticasone versus those treated with placebo (mean diff

296 salmeterol in a fixed-dose combination with fluticasone was associated with the risk of a serious as

297 ebo); the difference between montelukast and fluticasone was not significant (P = .14).

298 dian value) tended to show more benefit with fluticasone, whereas those with a smoking history of >11

299 We compared mice treated with fluticasone with controls at various timepoints after in

300 stent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26